BridgeMD
New treatment option for Tinnitus
Official title The Effect of Mild-gain Amplification on Tinnitus Perception in Normal Hearing Adults
ClinicalTrials.gov ID: NCT07489807
What this study is testing
- What it's testing
- This study investigated the effect of mild gain amplification (8dB covering 1 Hz to 8kHz) as tinnitus treatment for participants with normal hearing and compared these effects with an active placebo condition using hearing aids without amplification in a double-blinded crossover study. 12 participants with normal hearing and chronic tinnitus were included in the study.
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Daily bothersome tinnitus for at least 3 months (TFI\>15)
- Normal hearing (25 dB HL from 125 Hz to 8 kHz)
- Inexperienced hearing aid user
You likely can't join if
- Meniere's disease, Tosclerosis, Stapedectomy, Stapedotomy and Tympanoplasty
- Objective or pulsatile tinnitus
- Hearing thresholds \>25 dB from 125 Hz to 8 kHz
The study team makes the final eligibility decision.
Where it's taking place
- Lyngby, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyngby, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.